IR-902 is under clinical development by Immune Response BioPharma and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase III drugs for Secondary Progressive Multiple Sclerosis (SPMS) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how IR-902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IR-902 (NeuroVax) is under development for the treatment of secondary progressive multiple sclerosis. It is administered by intramuscular route. The vaccine candidate is based on FOXP3+ expression technology. It is a synthetic T cell receptor (TCR) peptide comprising contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-cells. It was under development for the treatment of pediatric multiple sclerosis.
Immune Response BioPharma overview
Immune Response BioPharma is a company that discovers and develops vaccines and drugs for auto-immune and infectious diseases. The company is headquartered in Atlantic City, New Jersey, the US.
For a complete picture of IR-902’s drug-specific PTSR and LoA scores, buy the report here.